Newsstand | Page 9 | Aplastic Anemia & MDS International Foundation


Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Advances in Myeloma, Lymphoma, and Bone Marrow Transplant Announced at the 2018 ASH Meeting

Originally Published: 12/03/2018
The American Society of Hematology (ASH) annual meeting is the world’s premier event devoted to the study of blood cancers and disorders. More than 25,000 people are attending the 2018 assembly, held December 1 through 4 in San Diego. Memorial Sloan Kettering researchers at the meeting have reported important progress in understanding and treating several blood cancers. Here are a few of the advances they’ve presented.

Cleveland Clinic Cancer Researcher Develops Personalized Prediction Model for Patients with Myelodysplastic Syndromes

Originally Published: 12/02/2018
At the American Society of Hematology (ASH) Annual Meeting, Cleveland Clinic medical hematologist and oncologist Aziz Nazha, M.D., will present results of a personalized prediction model that surpassed current prediction models for Myelodysplastic Syndromes (MDS).

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide

Originally Published: 12/02/2018
Increasing the number of hematopoietic stem and progenitor cells within an umbilical cord blood (UCB) graft shortens the time to hematopoietic recovery after UCB transplantation. In this study, we assessed the safety and efficacy of a UCB graft that was expanded ex vivo in the presence of nicotinamide and transplanted after myeloablative conditioning as a stand-alone hematopoietic stem-cell graft.

Twisting The Bone Marrow Stem Cell Niche

Originally Published: 12/01/2018
Niche Twist1 deficiency impairs hematopoietic stem cell function, homing and retention

AAMDSIF Employee Elise Harper Receives Public Citizen’s 2018 Phyllis McCarthy Annual Public Interest Award

Originally Published: 11/15/2018
AAMDSIF ( and Public Citizen ( are pleased to announce that Public Citizen’s 2018 Phyllis McCarthy Annual Public Interest Award has been awared to to Elise Harper, Database and Office Manager at the Aplastic Anemia and MDS International Foundation (AAMDSIF). Elise joined AAMDSIF in 2009 as a volunteer and immediately became indispensable to the staff. She was hired in 2010 and now manages the Foundation’s database, handles all administrative projects and support for the finance and development teams. One of her most important tasks is supervising three special...


Originally Published: 11/13/2018

Foundation Update Newsletter November 2018

Originally Published: 11/10/2018

Aplastic Anemia & MDS International Foundation Announces New Executive Director

Originally Published: 10/23/2018
Tuesday, October 23, 2018 - For Immediate Release APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION ANNOUNCES NEW EXECUTIVE DIRECTOR BETHESDA, MARYLAND –  The Aplastic Anemia & MDS International Foundation (AAMDSIF), the world's leading non-profit health organization dedicated to serving patients afflicted with bone marrow failure disease, announced today that Neil Horikoshi has been named the Foundation's new Chief Executive Officer and Executive Director.  Mr. Horikoshi succeeds Kathleen Weis, who resigned from her position to pursue new opportunities.            “On behalf of the...

Genomic Breakthroughs Offer Hope for New Strategies in AML

Originally Published: 10/23/2018
Results of a deep sequencing analysis demonstrated that mutations in 8 high-risk genes are associated with an acute myeloid leukemia (AML) diagnosis. These findings, explained Hetty Carraway, MD, lay the ground work for early detection studies and novel treatment strategies. “It is pretty provocative work, pretty exciting, and it really allows us to think more deeply about how we can impact and change that trajectory for patients,” said Carraway, who is vice chair of Strategy and Enterprise Development at Taussig Cancer Institute, Cleveland Clinic.

The MDS Clinical Research Consortium

Originally Published: 10/17/2018
The MDS Clinical Research Consortium (MDS- CRC) is an unprecedented, six-institution group designed to undertake unique studies and trials to advance treatments and improve outcomes for patients with myelodysplastic syndromes (MDS). Member institutions are six academic medical centers serving a high volume of MDS patients: Cleveland Clinic Taussig Cancer Institute Dana-Farber Cancer Institute H. Lee Moffitt Cancer Center and Research Institute  MD Anderson Cancer Center Weill Medical College of Cornell University Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The consortium is...